Vijaya Diagnostic Centre Ltd — Q4 FY26 earnings call
Summary generated by AI from the official transcript Vijaya Diagnostic Centre Ltd filed with BSE on 13 May 2026. Every statement cites a verbatim quote from that document — open any citation to read it. This is a record of what management said, not a recommendation. How we check these summaries
The short read
Vijaya Diagnostic reported consolidated Q4 FY'26 revenue of INR 219 crores, up 26.6% year-on-year, driven by 18.5% test volume growth and a change in test mix. EBITDA for the quarter rose 38.7% to INR 95.5 crores with margin at 43.5%, while full-year FY'26 revenue crossed INR 814 crores. Management discussed network expansion plans for FY'27 including new hubs and spokes, an automated lab in Panjagutta, and entry into genomic testing, alongside commentary on Pune, Kolkata and Bangalore cluster performance.
Numbers mentioned
Consolidated revenue: INR 219 crores (Q4 FY'26)
p. 4
“The consolidated revenue for the current quarter stood at INR 219 crores, reflecting a strong revenue growth rate of 26.6% Y-o-Y.”
Ankit Shah, page 4 of the filed PDF · View the filing
Test volume growth: 18.5% (Q4 FY'26)
p. 4
“And this strong revenue growth, just like the previous quarter was driven by test volume growth of 18.5% Y-o-Y.”
Ankit Shah, page 4 of the filed PDF · View the filing
EBITDA: INR 95.5 crores (Q4 FY'26)
p. 5
“EBITDA for the current quarter stood at INR 95.5 crores as compared to INR 68.9 crores in the corresponding quarter in the previous year, reflecting a Y-o-Y growth rate of 38.7%.”
Ankit Shah, page 5 of the filed PDF · View the filing
EBITDA margin: 43.5% (Q4 FY'26)
p. 5
“The EBITDA margin stood healthy at 43.5% in the current quarter with an improvement of 379 basis points Y-o-Y.”
Ankit Shah, page 5 of the filed PDF · View the filing
Profit after tax: INR 47.9 crores (Q4 FY'26)
p. 5
“The profit after tax for the current year -- for the current quarter stood at INR 47.9 crores, reflecting a strong growth of 37.5% and a PAT Margin also stood healthy at 21.8%.”
Ankit Shah, page 5 of the filed PDF · View the filing
Consolidated revenue: INR 814 crores (FY'26)
p. 5
“The consolidated revenue for the financial year ended FY'26 stood at INR 814 crores as against INR 681 crores in the previous financial year FY'25, reflecting a Y-o-Y growth of 19.5%.”
Ankit Shah, page 5 of the filed PDF · View the filing
EBITDA: INR 337 crores (FY'26)
p. 5
“EBITDA stood at INR 337 crores as against INR 273 crores in the previous financial year, registering a Y-o-Y growth of 23.3%.”
Ankit Shah, page 5 of the filed PDF · View the filing
EBITDA margin: 41.4% (FY'26)
p. 5
“EBITDA margin stood healthy at 41.4%, and the Profit After Tax was INR 173 crores with a margin of 21.2%.”
Ankit Shah, page 5 of the filed PDF · View the filing
Capital expenditure: INR 169 crores (FY'26)
p. 5
“Coming to the update on capital investment in the current period, the overall capex outlay has been INR 169 crores, inclusive of replacement capex.”
Ankit Shah, page 5 of the filed PDF · View the filing
PH Diagnostics revenue growth: 16% (Q4 FY'26)
p. 4
“Turning to PH, we delivered a year-on-year growth of 16%, primarily driven by network expansion and favorable seasonality during the quarter.”
Suprita Reddy, page 4 of the filed PDF · View the filing
Revenue per test: INR 488 (Q4 FY'26)
p. 4
“The revenue per test and revenue per Footfall stood at INR 488 and INR 1,808, respectively, during the current quarter.”
Ankit Shah, page 4 of the filed PDF · View the filing
What management said it would do
A record of statements made on the call, in the words management used. Parakho does not forecast, endorse or assess them, and their presence here is not a view on whether they will happen.
FY'27 capital expenditure — INR 140 crores to INR 150 crores · FY'27
stated firmly by Ankit Shah
p. 5
“For FY'27, the capital outlay for the new centers, including the lab, the new automated lab, is estimated to be INR 140 crores to INR 150 crores.”
Ankit Shah, page 5 of the filed PDF · View the filing
EBITDA margin — more than 40%
stated conditionally by Siva Rama Raju
p. 9
“So, keeping all this in mind, what we feel is, also taking both the investments on to technology and talent into consideration, we feel that we'll be able to comfortably deliver more than 40%.”
Siva Rama Raju, page 9 of the filed PDF · View the filing
New center additions — 4 to 5 hubs and 10 to 12 spokes · FY'27
stated firmly by Suprita Reddy
p. 4
“Coming to our expansion plan for FY'27, we would be commissioning 4 to 5 hubs and 10 to 12 spokes across the network.”
Suprita Reddy, page 4 of the filed PDF · View the filing
Pune (PH) revenue — double revenue · next three to five years
stated as an aspiration by Siva Rama Raju
p. 15
“we are very confident that in next three to five years, we'll be easily doubling up our revenue from where we are now.”
Siva Rama Raju, page 15 of the filed PDF · View the filing
Hyderabad growth — double-digit growth · 2 to 3 years
stated as an aspiration by Siva Rama Raju
p. 6
“we foresee that even in the near future of 2 to 3 years of term, we will still grow in double-digit in Hyderabad.”
Siva Rama Raju, page 6 of the filed PDF · View the filing
Digital marketing spend — doubling · current and next financial year
stated firmly by Siva Rama Raju
p. 13
“If you see last one financial year, we've almost spent roughly around INR 6 crores to INR 7 crores on digital marketing, where we see that cost, doubling in the current and the next financial year.”
Siva Rama Raju, page 13 of the filed PDF · View the filing
North India expansion — 3 to 5 years
stated firmly by Suprita Reddy
p. 17
“Probably, say another 3 to 5 years is something because, we have Karnataka and West Bengal to look at concentrate and grow with Pune already in that process.”
Suprita Reddy, page 17 of the filed PDF · View the filing
Maintenance capex — INR 10 crores to INR 15 crores · FY27
stated firmly by Siva Rama Raju
p. 17
“It'll be around INR 10 crores to INR 15 crores.”
Siva Rama Raju, page 17 of the filed PDF · View the filing
Q&A highlights
Management's answers to analyst questions, in Parakho's words rather than a transcript. Each row names who answered and carries the verbatim quote it was drawn from.
Management attributed growth to favorable seasons, market share gains due to quality, network breadth, technology and talent, without significant price premium.
Answered by Siva Rama Raju
Asked by Surya Patra: What is driving the ~20% growth in the mature Hyderabad market and how sustainable is it?
p. 6
“I think we are inching market share as and when there is a favorable season, we are inching the market share.”
Siva Rama Raju, page 6 of the filed PDF · View the filing
Management said operating leverage on the largely fixed cost base and faster-than-expected breakeven of new hubs drove the margin improvement.
Answered by Siva Rama Raju
Asked by Rajat Baldewa: What drove the EBITDA margin outperformance in Q4?
p. 8
“So, it is a mix of both the operating leverage and the break-even of new centers that have led to the 43.5% margin.”
Siva Rama Raju, page 8 of the filed PDF · View the filing
Management guided to comfortably delivering more than 40% margin, being conservative given new center dilution.
Answered by Siva Rama Raju
Asked by Anshul Agrawal: Will margin accretion in FY'27 be sharper given the mix of hubs versus spokes being commissioned?
p. 9
“So, keeping all this in mind, what we feel is, also taking both the investments on to technology and talent into consideration, we feel that we'll be able to comfortably deliver more than 40%.”
Siva Rama Raju, page 9 of the filed PDF · View the filing
Management said they evaluate 8-15 inorganic opportunities a year but remain selective, and current capex guidance reflects only executed leases.
Answered by Suprita Reddy
Asked by Anshul Agrawal: What are the plans for deploying the cash balance, including inorganic opportunities?
p. 9
“So if something comes up, there's almost close to about 8 to 15 assets that come to us on a yearly basis.”
Suprita Reddy, page 9 of the filed PDF · View the filing
Management said two centers opened in Q1 FY'26 broke even in under 9 months, and newer centers are expected to break even within a year.
Answered by Siva Rama Raju
Asked by Akshaya Shinde: How have the Kolkata hubs progressed and what is the breakeven trajectory for newer centers?
p. 12
“we expect the similar kind of ramp-up to happen at these centers, and we are confident of achieving the breakeven within 1 year of our guided timeline.”
Siva Rama Raju, page 12 of the filed PDF · View the filing
Management said implementation itself is not the challenge but regulatory validation and licensing for AI radiology tools takes time.
Answered by Suprita Reddy
Asked by Rishi Mody: Are there implementation risks with the ongoing tech investments (CRM, ERP, AI in radiology)?
p. 13
“So we can't just bring in something without validation. And validation requires certain paperwork, and those are very limited in nature as we speak as of today.”
Suprita Reddy, page 13 of the filed PDF · View the filing
Management said Pune growth was delayed versus original guidance due to integration efforts but expects to double revenue in three to five years.
Answered by Siva Rama Raju
Asked by Sumit Gupta: What is the medium-term outlook for the Pune (PH) cluster's growth and revenue per center?
p. 15
“But then we went very slow. We did not open centers also. We went very slow because after acquiring, we took one to one-and-a-half year to settle in ground-level things like changing software aligning the processes etc.”
Siva Rama Raju, page 15 of the filed PDF · View the filing
Management said they have not seen a significant change in testing demand tied to the drug, partly due to difficulty tracking prescriptions.
Answered by Suprita Reddy
Asked by Akash Shah: Is there any traction from increased uptake of the recently generic weight-loss drug driving diagnostic demand?
p. 18
“We've not seen actual requests for a GLP package come in yet in the geographies that we operate in.”
Suprita Reddy, page 18 of the filed PDF · View the filing
Management firmly ruled out franchising, stating all centers are company-owned and operated.
Answered by Suprita Reddy
Asked by Ayush Agrawal: Is the company considering a franchise model in future?
p. 19
“At the moment, I would not be able to comment on the future, but all of these centers that we operate today are company-owned and company-operated.”
Suprita Reddy, page 19 of the filed PDF · View the filing
Risks flagged
Capacity constraints at some PH (Pune) centers limiting growth
p. 11
“So yes, we have a little bit of capacity constraint. But then we have seen growth even in the existing centers, but it is in the low-single-digit, but it's a mix of both.”
Siva Rama Raju, page 11 of the filed PDF · View the filing
Regulatory validation and licensing requirements slow rollout of AI diagnostic tools
p. 13
“So probably something that we can release to customers is not going to be more than 6 or 7.”
Suprita Reddy, page 13 of the filed PDF · View the filing
Corporate wellness client churn due to price sensitivity and aggregators
p. 19
“But then at the same time with lot of aggregatorsin place, right, and corporates-- few corporates being price sensitive, we keep seeing the churn.”
Siva Rama Raju, page 19 of the filed PDF · View the filing
Incremental cost of building second-in-line talent in new geographies pressuring near-term margins
p. 8
“So, in fact, in many of the newer geographies, we are developing the second in line because we feel the talent is important for us to scale the centers there. So, this incremental cost will be for this financial year.”
Siva Rama Raju, page 8 of the filed PDF · View the filing
Generated by claude-sonnet-5. Source: the transcript as filed with BSE. We link to the exchange's copy; we do not host transcripts. Parakho is a data and screening tool, not an investment adviser — nothing here is a recommendation to buy, sell or hold.